吸入瑞莫杜林即将进入临床
2019年04月20日 【健康号】 南景龙     阅读 7480

Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
March 11, 2019
• LIQ861 was well-tolerated in PAH patients at two months of treatment
• INSPIRE enrollment complete, including PK sub-study
• Anticipate submitting NDA for LIQ861 to the FDA in late 2019
RESEARCH TRIANGLE PARK, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line results of its pivotal Phase 3 INSPIRE study in patients with pulmonary arterial hypertension (“PAH”) treated with LIQ861, the first inhaled dry powder formulation of treprostinil. Initial analysis indicates the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint.


提示x

您已经顶过了!

确认
''
|
南景龙
主任医师
内蒙古自治区人民医院
心血管内科
冠心病、高血压、心衰、心律失常等疾病的诊治及冠心病、肺动脉高血压的干细胞诊疗。
去Ta主页
Ta最近的文章 更多 |

热门文章

请选择举报原因
垃圾广告信息
色情低俗内容
违规有害信息
侵犯隐私、虚假谣传